Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Stuart Herlands

Internal Medicine Glastonbury, CT Medical Doctor

NPI 1336150309 CMS profile 151364

55 Nye Rd, Glastonbury, CT 06033

Open in the dashboard

General payments

$1,659

105 records reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Stuart Herlands of Glastonbury, CT is reported in the CMS Open Payments database as having received $1,659 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $1,659 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stuart Herlands
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Stuart Herlands were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Stuart Herlands Internal Medicine median Middle half National median
2019 $1,659 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program year 2019
  1. Novo Nordisk Inc $356 23 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $233 13 payments
  3. AstraZeneca Pharmaceuticals LP $142 10 payments
  4. Sanofi-Aventis U.S. LLC $118 7 payments
  5. Amgen Inc. $109 6 payments
  6. Pfizer Inc. $66 5 payments
  7. Lilly USA, LLC $62 4 payments
  8. Janssen Pharmaceuticals, Inc $57 3 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $50 3 payments
  10. Amarin Pharma Inc. $48 3 payments
  11. Other $418 28 payments

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $1,653 104 payments
  2. Education $6 1 payment
Products named General payments · program year 2019
  1. Ozempic $188 11 payments
  2. Tresiba $168 12 payments
  3. Victoza $168 12 payments
  4. Xultophy 100/3.6 $167 11 payments
  5. JARDIANCE $145 8 payments
  6. FARXIGA $142 10 payments
  7. TOUJEO $97 6 payments
  8. GLYXAMBI $82 4 payments
  9. SPIRIVA RESPIMAT $72 4 payments
  10. AIMOVIG $70 4 payments
  11. Other $1,293 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 131 drugs

Part D claims

9,682

Median for Internal Medicine: 777

Drug cost

$1,010,174

Median for Internal Medicine: $73,373

Branded share of claims

20.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 158 $151,346
Ozempic Semaglutide Brand 120 $128,923
Trulicity Dulaglutide Brand 77 $119,886
Jardiance Empagliflozin Brand 92 $93,366
Januvia Sitagliptin Phosphate Brand 47 $61,486
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 58 $48,161
Prolia Denosumab Brand 28 $48,001
Tradjenta Linagliptin Brand 37 $39,340
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 56 $33,481
Xarelto Rivaroxaban Brand 28 $31,259

The 10 drugs with the highest cost, of 131 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$129,509

Of which drugs: $18,156

Medicare patients

313

Average age 77

Services billed

3,549

145 women, 168 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 39%
Chronic kidney disease 29%
Ischemic heart disease 25%
Atrial fibrillation 24%
Diabetes 21%
Depression 21%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 32 32 $9,310
Vaccine for influenza for injection into muscle 90653 Office 69 69 $4,463
Sarscv2 vac 30mcg trs-suc im 91320 Office 21 22 $3,113

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record